ArticleFrontiers in immunology2019
A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Surface-modified nanocarriers in the design of targeted drug delivery systems for parasitic diseases: a comprehensive review.BMC chemistry · 2026Review
- Extracellular vesicles as vaccine platforms: emerging opportunities for malaria.Frontiers in immunology · 2026Review
- Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells.Frontiers in immunology · 2025Article
- MicroRNA Guided In Silico Drug Repositioning for Malaria.Acta parasitologica · 2024Article
- PfSPZ Vaccine induces focused humoral immune response in HIV positive and negative Tanzanian adults.EBioMedicine · 2024Article
- Genetic diversity of merozoite surface protein-5 (MSP-5) of Plasmodium vivax isolates from Malaria patients in Iran.BMC infectious diseases · 2023Article
- Malaria therapeutics: are we close enough?Parasites & vectors · 2023Review
- Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria.Parasite epidemiology and control · 2022Review
- Myeloid-derived suppressor cells and vaccination against pathogens.Frontiers in cellular and infection microbiology · 2022Review
- Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory.Frontiers in immunology · 2022Review
- Potential of nanoformulations in malaria treatment.Frontiers in pharmacology · 2022Review
- Supramolecular Nanostructures for Vaccines.Biomimetics (Basel, Switzerland) · 2021Review
- Chemical Conjugation Strategies for the Development of Protein-Based Subunit Nanovaccines.Vaccines · 2021Review
- Solubility Controlling Peptide Tags of Opposite Charges Generate a Bivalent Immune Response Against Dengue ED3 Serotypes 3 and 4.Frontiers in immunology · 2021Article
- Polymeric nanoparticle vaccines to combat emerging and pandemic threats.Biomaterials · 2021Review
- Article
- A systematic mutational analysis identifies a 5-residue proline tag that enhances the in vivo immunogenicity of a non-immunogenic model protein.FEBS open bio · 2020Article
- Functional Recognition by CD8+ T Cells of Epitopes with Amino Acid Variations Outside Known MHC Anchor or T Cell Receptor Recognition Residues.International journal of molecular sciences · 2020Article
- Biodegradable PLGA-Vaccines · 2020Article
- Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS biomaterials science & engineering · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria remains a significant health problem in many tropical and sub-tropical regions. The development of vaccines against the clinically active blood-stage of infection needs to consider variability and polymorphism in target antigens, and an adjuvant system able to induce broad spectrum immunity comprising both antibodies and helper T cells. Moreover, recent studies have shown some conventional pro-inflammatory adjuvants can also promote expansion of immunosuppressive regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC), both of which could negatively impact malaria disease progression. Herein, we explore the ability of a model nanoparticle delivery system (polystyrene nanoparticles; PSNPs), previously proven to not induce conventional inflammation, Treg or MDSC, to induce immunity to MSP4/5 from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.